Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.50 |
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185825 | 0.87 | GRM5 (0.53) | KDM4E | |
| SCHEMBL4192471 | 0.85 | L3MBTL1 (0.58) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23246095 | 0.85 | KCNQ3 (0.57) | RAB9ASMN1; SMN2 | |
| SCHEMBL23246009 | 0.84 | KCNQ3 (0.52) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4194916 | 0.84 | PTGS1 (0.51) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23246023 | 0.81 | NPC1 (0.53) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4178804 | 0.80 | PTGS1 (0.58) | RAB9ANPC1 | |
| SCHEMBL168618 | 0.80 | MEN1 (0.63) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1198985 | 0.77 | NPC1 (0.58) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16692723 | 0.76 | KMT2A (0.44) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | ALOX15, ALOX12, ALOX15B | RAB9A 3588/4885NPC1 2790/4885SMN1; SMN2 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.